Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 12/20 | 0.56 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.43 |
| ▸ | CCNK | O75909 | 3/20 | 0.43 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.39 |
| ▸ | CDK9 | P50750 | 2/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23911222 | 0.88 | USP7 (0.71) | USP7NUDT1CCNKCDK12CCNT1 | |
| SCHEMBL23921917 | 0.88 | USP7 (0.71) | USP7NUDT1CCNKCDK12CCNT1 | |
| SCHEMBL23921918 | 0.88 | USP7 (0.71) | USP7NUDT1CCNKCDK12CCNT1 | |
| SCHEMBL23911387 | 0.87 | USP7 (0.56) | USP7CCNKCDK12CCNT1CDK9 | |
| SCHEMBL23911239 | 0.87 | USP7 (0.56) | USP7CCNKCDK12CCNT1CDK9 | |
| SCHEMBL23910700 | 0.86 | USP7 (0.55) | USP7CCNKCDK12CCNT1CDK9 | |
| SCHEMBL23910772 | 0.85 | USP7 (0.53) | USP7CCNKCDK12CCNT1CDK9 | |
| SCHEMBL23911640 | 0.85 | USP7 (0.76) | USP7CCNKCDK12 | |
| SCHEMBL23911635 | 0.85 | USP7 (0.54) | USP7CCNKCDK12CCNT1CDK9 | |
| SCHEMBL23910909 | 0.84 | USP7 (0.52) | USP7CCNKCDK12CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | USP7 1/4885NUDT1 2868/4885CCNK 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.